TC served as Executive Chairman at Cydy from January 2017 to mid 2018 and resigned as COB in December 2018.
There is zero published information or 3rd party support for the premise that he was “removed”.
Nader has implied this lie, but in the same breath said he did not dilute the company, while doubling the share count SINCE TC left. Hmm, who could be the liar here?
During the timeframe that Tony C was Executive Chairman, CYDY COMPLETED THE ONLY SUCCESSFUL TRIAL IN ITS HISTORY.
TC put the executive comp plan in place when he became chairman of the board in 2012. Since he left, Nader and the board have tried to circumvent the comp plan twice and twice TC, the guy looking out for shareholders, initiated legal action forcing return of the shares and a scathing rebuke by the presiding Magistrate.
ON December 31, 2018 about 300 million shares were outstanding. As of today 612 million shares are outstanding doubling outstanding shares in 2.5 years.
I know … Nader does not know what dilution means!
Since TC left, on his own accord, Nader has diluted the CYDY by 312 Million Shares, settled 2 lawsuits for unjust enrichment and has been rebuked by 3 government entities.
Now we find by the hand of another independent arbitrator that Nader forced out Pestell because he would not do unethical deeds demanded Nader by preparing an unsafe trial protocol for patients. The cost is about $7.6 million for the cash strapped company.
Since NP forced out Pestell for refusing to lie and violate his ethical requirements, we will never know if that acquisition could have been successful. I do not know who initiated the acquisition, but the failure is 100 percent on Nader. It is in the record.
Nader was unable to complete the HIV BLA without TC, and NP and SK have NOT COMPLETED ONE SUCCESSFUL TRIAL with out Tony C.
THEY DID GET REBUKED BY THE FDA, SEC, DELAWARE CHANCERY COURT MAGISTRATE, THEIR OWN INTERNAL INVESTIGATORS, and A THIRD PARTY ARBITER in the Pestell case.
Every single item mentioned is in the record for independent verification.